Skip to main content
European Commission logo
Live, work, travel in the EU
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

Scientific literature on COVID-19 Test Methods and Devices - detail

Comparison of different serological assays for SARS-CoV-2 in real life

DOI
10.1016/j.jcv.2020.104569 
Detection Principle
ImmunoAssay-Antigen
Target
ABBOTT: Nucloecapsid, BIORAD Spike1, LIAISON Spike1/2, WATAI RBD
Testing Method Category
mixed
Testing Method
SARS-CoV-2 nucleocapsid for ABBOTT and BIORAD, Spike 1 for EUROIMMUN, Spike 1 and 2 for LIAISON and receptor binding domain (RBD) for WANTAI
Testing Method - Additional Info
Comparison of different serological assays for SARS-CoV-2 in real life
Reported Performance
Sensitivity for hospitalized patients WANTAI: 100%, Sensitivity for hospitalized patients BIORAD: 100%, Sensitivity for hospitalized patients EUROIMMUN: 100%, Sensitivity for hospitalized patients ABBOTT: 100%, Sensitivity for hospitalized patients LIAISON: 100%. 31 days after the PCR sample, the different techniques showed a positive signal for 100 % of patients with WANTAI and EUROIMMUN (21/21), 95 % with BIORAD and LIAISON (20/21) and 90 % with ABBOTT (19/21)
Sample Size
168 patients
Peer-reviewed
yes

The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements